AMT licenses two AAV patents from Targeted Genetics
Dutch gene therapy firm Amsterdam Molecular Therapeutics BV says that it has acquired a non-exclusive license to two patents covering adeno-associated viral vectors that are owned by USA-based biotechnology firm Targeted Genetics. AMT explained that the license would allow it to develop and commercialize its lead product candidate AMT-011 as a treatment for lipoprotein lipase (LPL) deficiencies.
AMT added that AMT-011, which was granted Orphan Drug designation by the European Medicines Agency (EMEA), has shown efficacy as a replacement for LPL gene function in several models of the condition, and has since entered Phase I/II assessment. Financial terms of the deal were not provided.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze